LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
Dennis Schmidt Pedersen joined LEO Pharma in 2017 as Senior Human Resource Business Partner and is currently Global HR Lead. Before joining LEO Pharma, Dennis was Chief Human Resources Officer at SOBI, and held positions at Ferring Pharmaceuticals, Genzyme as well as Takeda. He has a background as Army Officer in the Danish Army.
“Dennis Schmidt Pedersen brings a wealth of experience as HR leader in the life-sciences industry to his new role, having helped companies during major strategic shifts such as mergers and acquisitions and expansion into new therapeutic areas. With his demonstrated success in building effective organizations, he will be a strong support in executing on our ambition to become a global leader in medical dermatology, positioning ourselves for long-term growth driven by innovation,” said Catherine Mazzacco, President and CEO of LEO Pharma. “I am also very pleased that we promote an internal candidate for this role, underlining the quality of our internal talent pool and talent work,” Catherine Mazzacco continued.
Dennis Schmidt Pedersen succeeds Mette Vestergaard who has decided to leave LEO Pharma for an external opportunity.
Contacts
LEO Pharma A/S
Henrik Kyndlev
+45 31406180
hdtdk@leo-pharma.com
Images
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year26.8.2024 14:00:00 CEST | Pressemeddelelse
Six-month interim report (H1) 2024 (Unaudited) - NOT FOR UK USE / NOT INTENDED FOR UK MEDIA
Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis21.8.2024 15:00:00 CEST | Pressemeddelelse
Results from the randomized, double-blind period of the phase 3 clinical trial with TMB-001 – the ASCEND trial – show that the primary and key secondary endpoints were not met. The trial investigated TMB-001 in patients 6 years or older with moderate to severe congenital ichthyosis. The majority of adverse events observed were non-serious localized skin reactions of mild or moderate severity. The trial results do not support submission of a New Drug Application to the US FDA. NOT FOR UK USE – NOT INTENDED FOR UK MEDIA
Change in the Board of Directors of LEO Pharma31.7.2024 10:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, July 31, 2024 – Today, LEO Pharma A/S announced that non-executive director Jan van de Winkel has decided to step down from the Board of Directors of LEO Pharma effective August 1, 2024 due to increasing time commitments from his primary executive position as Chief Executive Officer of Genmab A/S. Jan van de Winkel joined the Board of Directors in March, 2017. Chair of the Board of Directors, Jesper Brandgaard said: “I would like to express my sincere gratitude to Jan for his loyal service and valuable contributions to LEO Pharma as a non-executive board member throughout times of great change and transformation. I am pleased that Jan has offered to provide his advice to the Chairmanship in the process leading up to the potential public listing of LEO Pharma.”
LEO Pharma Receives Positive CHMP Opinion of Anzupgo® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema (CHE)26.7.2024 08:00:00 CEST | Pressemeddelelse
The positive opinion marks the latest step towards marketing authorization in the European Union (EU), with a final decision from the European Commission (EC) now pending. If approved, delgocitinib cream will be the first topical treatment specifically indicated for adults with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate. The positive opinion is based on results from the DELTA phase 3 program, which includes the randomized, vehicle-controlled DELTA 1 and DELTA 2 clinical trials, (1,2,3) and the DELTA 3 open-label extension trial.(4)
LEO Pharma Announces Publication of Chronic Hand Eczema Phase 3 Data in The Lancet19.7.2024 08:00:00 CEST | Pressemeddelelse
The Lancet publishes data from the pivotal DELTA 1 and DELTA 2 trials, marking the first time an investigational topical pan-Janus kinase (JAK) inhibitor for chronic hand eczema (CHE) has been featured in the journal.1 The DELTA 1 and DELTA 2 trials investigated the safety and efficacy of investigational delgocitinib cream in adult patients with moderate to severe CHE.2,3
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom